Document is current
Any future updates will be listed below
-
Authors
Wen, Lexiaochuan
Miyagi, Hiroko
Spiess, Philippe E. https://orcid.org/0000-0002-5723-1972
Yu, Alice
Mendelsohn, Cathy L. https://orcid.org/0000-0002-4026-4073
Tan, Wei Shen https://orcid.org/0000-0002-6119-4043
Psutka, Sarah P.
Lerner, Seth P. https://orcid.org/0000-0002-6379-2581
Cheng, Liang https://orcid.org/0000-0001-6049-5293
Dyrskjøt, Lars https://orcid.org/0000-0001-7061-9851
Meeks, Joshua J. https://orcid.org/0000-0002-5444-5510
Shariat, Shahrokh F.
Gontero, Paolo
Pradere, Benjamin https://orcid.org/0000-0002-7768-8558
Steinberg, Gary D.
Kamat, Ashish M. https://orcid.org/0000-0003-3546-9928
Li, Roger https://orcid.org/0000-0003-1274-7200
- License Information
-
More Information
Article History
Accepted: 15 July 2025
First Online: 10 September 2025
Competing interests
: S.P.L declares patent: TCGA classifier; clinical trials: Aura Bioscience, FKD, JBL (SWOG), Merck (Alliance), QED Therapeutics, Surge Therapeutics; advisory board/consulting fee: Aura Bioscience, Astra Zeneca, BMS, Pfizer/EMD Serono, Protara, Surge Therapeutics, Immunity Bio UroGen, Verity, Gilead, FKD, Viventa; honoraria: Grand Rounds Urology, UroToday. J.J.M. declares advisory boards/consulting: Merck, AstraZeneca, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferring, CG Oncology, Calibr, Immunity Bio, Protara, Photocure. S.P.P. declares research funding: National Institute on Aging, Bladder Cancer Advocacy Network, PRIME Education, Inc, Janssen; guidelines committee: American Urological Association: Upper Tract Urothelial Carcinoma Guidelines 2023 and AUA Practice Guidelines Committee; advisory/consulting: Janssen (SunRise-4 Global Co-PI), Immunity Bio, Merck, CG Oncology, Pfizer; editorial boards: European Urology, Bladder Cancer; steering committees/leadership: Bladder Cancer Advocacy Network, KCCure/Kidney Cancer Association/International Kidney Cancer Society; educational company presentations given: PeerView, MedScape, UroToday. A.M.K. declares patent: CyPRIT (Anderson Cancer Center #00043705); grants/contracts: FKD Therapies, Patient-Centered Outcomes Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostis, SWOG; advisory board/consulting: Astellas Pharma, Atonco Pharma, Biologic Dynamics, Bristol-Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merk, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio, Theralase, urogen Pharma, US Biotest, Valar Labs, Vivet Therapeutics; boards/committee: IBCG, European Urology Oncology, Journal of Urology, UroToday, World Bladder Cancer patient Coalition, American Urological Association. L.D. declares funding agreement: 2i Genomics, Veracyte, Natera, AstraZeneca, Photocure and Ferring; advisory/consulting: Ferring, MSD, Cystotech, AstraZeneca and UroGen; honoraria: AstraZeneca, Pfizer and Roche and travel support from MSD. R.L. declares research support: Predicine; Valar labs; Johnson & Johnson; scientific adviser/consultant: BMS, Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson, AstraZeneca, enGene, Valar Labs; honoraria: UroToday, IBCG, MashUP Media, MJH Lifesciences; travel: Predicine, CG Oncology, Johnson & Johnson. P.E.S. declares vice-chair of the NCCN bladder and penile cancer panel. All other authors declare no competing interests.
